Regeneron Pharmaceuticals (REGN) is back in focus after the World Health Organization recommended its antibody therapy maftivimab for Ebola trials, along with renewed attention on its wider R&D platform and expanding collaborations.

Despite the recent WHO spotlight on maftivimab and expanded oncology collaborations, the stock has lost momentum. The 30-day share price return is down 14.97% and the year-to-date share price return is down 21.15%, even as the 1-year total shareholder return is 16.3%.

If you are watching how healthcare breakthroughs can reshape portfolios, this is a good moment to scan other opportunities in AI driven drug development using the 40 healthcare AI stocks

So with Regeneron’s share price sliding recently, even as its pipeline, collaborations and cash position draw fresh attention, is the stock offering a rare entry point or is the market already pricing in the next leg of growth?

Most Popular Narrative: 30.1% Undervalued

Regeneron’s most followed narrative points to a fair value of $875.31 per share versus the last close at $612.14, putting valuation and pipeline expectations firmly in the spotlight.

Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronnextamab), genetic medicines, and obesity positions the company to benefit from demographic driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline driven earnings upside.

Curious what sits behind that confidence in future earnings, margins and valuation multiples? The narrative leans on specific growth rates, profitability shifts and a higher future P/E to justify the gap between today’s price and its fair value.

Result: Fair Value of $875.31 (UNDERVALUED)

However, this upbeat narrative can unravel quickly if EYLEA competition and pricing pressure hit harder than expected, or if heavier R&D and manufacturing spend fails to translate into commercially successful drugs.

Next Steps

With sentiment clearly split between recent price weakness and longer term optimism, this is a good time to review the details yourself and act quickly. To see what investors view as the key upsides, take a closer look at the 4 key rewards.

Looking for more investment ideas?

If you stop with one stock, you risk missing other opportunities that might fit your goals even better, so broaden your watchlist while you are here.

• Spot potential value opportunities early by scanning companies that screen as 44 high quality undervalued stocks.
• Prioritize resilience by reviewing stocks highlighted in the 70 resilient stocks with low risk scores.
• Hunt for potential up-and-comers by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.